苔藓表达糖基化优化的人补体因子H用于补体疾病治疗
遗传性补体调节蛋白缺陷可致非典型溶血性尿毒症综合征、C3肾小球病及年龄相关性黄斑变性,多数突变影响补体因子H。本研究在苔藓(Physcomitrella patens)中表达去除植物特异性糖残基的重组人因子H,每升初始培养物经多步纯化得约1 mg纯化蛋白;该因子H体外补体调节活性与血浆来源因子H相似,可阻断LPS诱导的旁路途径激活及非典型溶血性尿毒症综合征患者血清诱导的溶血,并在小鼠C3肾小球病模型中减少C3沉积、升高血清C3水平。
要点
- 苔藓表达的重组人因子H经糖基化优化,每升初始培养物经多步纯化得约1 mg纯化蛋白。
- 该因子H体外补体调节活性与血浆来源因子H相似。
- 该因子H可阻断LPS诱导的旁路途径激活及非典型溶血性尿毒症综合征患者血清诱导的溶血。
核心结论
- 作者认为苔藓表达的重组人因子H是治疗补体调节异常患者的有前景的药物产品。
研究设计与样本
- 在苔藓(Physcomitrella patens)中表达去除蛋白N-糖链上潜在免疫原性植物特异性糖残基的重组人因子H,并经多步纯化。
主要发现
- 每升初始苔藓培养物经多步纯化后获得约1 mg纯化苔藓来源人因子H。
- 糖基化优化的因子H体外补体调节活性与血浆来源因子H相似。
- 该因子H有效阻断LPS诱导的旁路途径激活及非典型溶血性尿毒症综合征患者血清诱导的溶血。
- 在小鼠C3肾小球病模型中,注射苔藓来源因子H减少C3沉积并升高血清C3水平。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Genetic defects in complement regulatory proteins can lead to severe renal diseases, including atypical hemolytic uremic syndrome and C3 glomerulopathies, and age-related macular degeneration. The majority of the mutations found in patients with these diseases affect the glycoprotein complement factor H, the main regulator of the alternative pathway of complement activation. Therapeutic options are limited, and novel treatments, specifically those targeting alternative pathway activation, are highly desirable. Substitution with biologically active factor H could potentially treat a variety of diseases that involve increased alternative pathway activation, but no therapeutic factor H is commercially available. We recently reported the expression of full-length recombinant factor H in moss (Physcomitrella patens). Here, we present the production of an improved moss-derived recombinant human factor H devoid of potentially immunogenic plant-specific sugar residues on protein N-glycans, yielding approximately 1 mg purified moss-derived human factor H per liter of initial P. patens culture after a multistep purification process. This glycosylation-optimized factor H showed full in vitro complement regulatory activity similar to that of plasma-derived factor H and efficiently blocked LPS-induced alternative pathway activation and hemolysis induced by sera from patients with atypical hemolytic uremic syndrome. Furthermore, injection of moss-derived factor H reduced C3 deposition and increased serum C3 levels in a murine model of C3 glomerulopathy. Thus, we consider moss-produced recombinant human factor H a promising pharmaceutical product for therapeutic intervention in patients suffering from complement dysregulation.
引用
- Michelfelder S, Parsons J, Bohlender LL, et al. Moss-Produced, Glycosylation-Optimized Human Factor H for Therapeutic Application in Complement Disorders. J Am Soc Nephrol. 2016. PMID: 27932477. doi:10.1681/ASN.2015070745
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。